Literature DB >> 9719789

Risk adjustment of mental health and substance abuse payments.

S L Ettner1, R G Frank, T G McGuire, J P Newhouse, E H Notman.   

Abstract

This study used 1992 and 1993 data from private employers to compare the performance of various risk adjustment methods in predicting the mental health and substance abuse expenditures of a nonelderly insured population. The methods considered included a basic demographic model, Ambulatory Care Groups, modified Ambulatory Diagnostic Groups and Hierarchical Coexisting Conditions (a modification of Diagnostic Cost Groups), as well as a model developed in this paper to tailor risk adjustment to the unique characteristics of psychiatric disorders (the "comorbidity" model). Our primary concern was the amount of unexplained systematic risk and its relationship to the likelihood of a health plan experiencing extraordinary profits or losses stemming from enrollee selection. We used a two-part model to estimate mental health and substance abuse spending. We examined the R2 and mean absolute prediction error associated with each risk adjustment system. We also examined the profits and losses that would be incurred by the health plans serving two of the employers in our database, based on the naturally occurring selection of enrollees into these plans. The modified Ambulatory Diagnostic Groups and comorbidity model performed somewhat better than the others, but none of the models achieved R2 values above .10. Furthermore, simulations based on actual plan choices suggested that none of the risk adjustment methods reallocated payments across plans sufficiently to compensate for systematic selection.

Entities:  

Mesh:

Year:  1998        PMID: 9719789

Source DB:  PubMed          Journal:  Inquiry        ISSN: 0046-9580            Impact factor:   1.730


  25 in total

1.  Ignoring small predictable profits and losses: a new approach for measuring incentives for cream skimming.

Authors:  E M van Barneveld; L M Lamers; R C van Vliet; W P van de Ven
Journal:  Health Care Manag Sci       Date:  2000-02

2.  Risk adjustment alternatives in paying for behavioral health care under Medicaid.

Authors:  S L Ettner; R G Frank; T G McGuire; R C Hermann
Journal:  Health Serv Res       Date:  2001-08       Impact factor: 3.402

3.  Comparing alternative risk-adjustment models.

Authors:  M S Hendryx; G B Teague
Journal:  J Behav Health Serv Res       Date:  2001-08       Impact factor: 1.505

4.  Risk adjustment of Florida mental health outcomes data: concepts, methods, and results.

Authors:  M G Dow; T L Boaz; D Thornton
Journal:  J Behav Health Serv Res       Date:  2001-08       Impact factor: 1.505

5.  Risk adjustment in the Hoosier Assurance Plan: impact on providers.

Authors:  R N DeLiberty; F L Newman; E O Ward
Journal:  J Behav Health Serv Res       Date:  2001-08       Impact factor: 1.505

6.  Do adjusted clinical groups eliminate incentives for HMOs to avoid substance abusers? Evidence from the Maryland Medicaid HealthChoice program.

Authors:  Susan L Ettner; Steven Johnson
Journal:  J Behav Health Serv Res       Date:  2003 Jan-Feb       Impact factor: 1.505

7.  The effect of expanded mental health benefits on treatment initiation and specialist utilization.

Authors:  Richard C Lindrooth; Anthony T Lo Sasso; Ithai Z Lurie
Journal:  Health Serv Res       Date:  2005-08       Impact factor: 3.402

8.  Evaluating the Impact of Integrated Care on Service Utilization in Serious Mental Illness.

Authors:  Heidi C Waters; Michael F Furukawa; Shari L Jorissen
Journal:  Community Ment Health J       Date:  2018-06-14

9.  What Oregon's parity law can tell us about the federal Mental Health Parity and Addiction Equity Act and spending on substance abuse treatment services.

Authors:  K John McConnell; M Susan Ridgely; Dennis McCarty
Journal:  Drug Alcohol Depend       Date:  2012-02-28       Impact factor: 4.492

10.  Diagnostic cost groups (DCGs) and concurrent utilization among patients with substance abuse disorders.

Authors:  Amy K Rosen; Susan A Loveland; Jennifer J Anderson; Cheryl S Hankin; James N Breckenridge; Dan R Berlowitz
Journal:  Health Serv Res       Date:  2002-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.